

Dirk Westermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6004686/publications.pdf>

Version: 2024-02-01

115
papers

6,812
citations

87843

38
h-index

66879

78
g-index

120
all docs

120
docs citations

120
times ranked

9050
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. <i>JAMA Cardiology</i> , 2020, 5, 1281.	3.0	644
2	Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 44-52.	1.6	493
3	Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction. <i>Circulation</i> , 2008, 117, 2051-2060.	1.6	403
4	Concomitant implantation of Impella [®] on top of venoarterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. <i>European Journal of Heart Failure</i> , 2017, 19, 404-412.	2.9	402
5	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>Circulation</i> , 2019, 139, 1249-1258.	1.6	353
6	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoaerterial Extracorporeal Membrane Oxygenation. <i>Circulation</i> , 2020, 142, 2095-2106.	1.6	269
7	Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 380, 2529-2540.	13.9	230
8	Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1913.	3.8	188
9	Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. <i>JAMA Cardiology</i> , 2016, 1, 397.	3.0	186
10	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. <i>Basic Research in Cardiology</i> , 2007, 102, 500-507.	2.5	180
11	Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 620-632.	1.2	147
12	High-sensitivity assays for troponin in patients with cardiac disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 472-483.	6.1	144
13	Cardiac fibroblasts support cardiac inflammation in heart failure. <i>Basic Research in Cardiology</i> , 2014, 109, 428.	2.5	128
14	Application of the SCAI classification in a cohort of patients with cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E213-E219.	0.7	122
15	Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy. <i>Diabetes</i> , 2007, 56, 1834-1841.	0.3	121
16	Unloading of the Left Ventricle During Venoaerterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock. <i>JACC: Heart Failure</i> , 2018, 6, 1035-1043.	1.9	105
17	Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy. <i>Diabetes</i> , 2009, 58, 1373-1381.	0.3	102
18	Molecular consequences of SARS-CoV-2 liver tropism. <i>Nature Metabolism</i> , 2022, 4, 310-319.	5.1	98

#	ARTICLE	IF	CITATIONS
19	Discrimination of patients with type 2 myocardial infarction. <i>European Heart Journal</i> , 2017, 38, 3514-3520.	1.0	96
20	Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. <i>Circulation</i> , 2018, 138, 2298-2300.	1.6	92
21	Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure. <i>Hypertension</i> , 2008, 52, 1068-1075.	1.3	91
22	Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. <i>Circulation Research</i> , 2019, 125, 328-340.	2.0	86
23	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. <i>Circulation</i> , 2011, 124, 2082-2093.	1.6	81
24	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. <i>Circulation</i> , 2019, 140, 1530-1539.	1.6	78
25	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 1295-1303.	1.4	69
26	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. <i>Basic Research in Cardiology</i> , 2012, 107, 308.	2.5	66
27	Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. <i>Basic Research in Cardiology</i> , 2009, 104, 499-509.	2.5	63
28	Hemodynamic Effects of Mechanical Circulatory Support Devices in Ventricular Septal Defect. <i>Circulation: Heart Failure</i> , 2019, 12, e005981.	1.6	62
29	Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I. <i>Clinical Chemistry</i> , 2017, 63, 394-402.	1.5	57
30	Cardiac glial cells release neurotrophic S100B upon catheter-based treatment of atrial fibrillation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	57
31	Diagnostic Evaluation of a High-Sensitivity Troponin I Point-of-Care Assay. <i>Clinical Chemistry</i> , 2019, 65, 1592-1601.	1.5	56
32	Temporal trends in incidence and outcome of acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2020, 109, 1186-1192.	1.5	54
33	Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2017, 227, 272-277.	0.8	49
34	Immunomodulation and matrix metalloproteinases in viral myocarditis. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 468-473.	0.9	48
35	Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. <i>European Heart Journal</i> , 2020, 41, 3753-3761.	1.0	48
36	Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. <i>Journal of Critical Care</i> , 2020, 57, 259-263.	1.0	47

#	ARTICLE	IF	CITATIONS
37	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 604-612.	0.4	45
38	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. <i>Cardiovascular Research</i> , 2022, 118, 542-555.	1.8	42
39	Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. <i>European Heart Journal</i> , 2016, 37, 1807-1814.	1.0	41
40	Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome. <i>Biomolecules</i> , 2018, 8, 60.	1.8	39
41	Cardiac Fibroblasts Aggravate Viral Myocarditis: Cell Specific Coxsackievirus B3 Replication. <i>Mediators of Inflammation</i> , 2014, 2014, 1-14.	1.4	37
42	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2022, 175, 101-113.	2.0	37
43	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1949-1962.	1.2	36
44	Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. <i>Resuscitation</i> , 2019, 136, 14-20.	1.3	33
45	Procedural volume and outcomes in patients undergoing VA-ECMO support. <i>Critical Care</i> , 2020, 24, 291.	2.5	32
46	Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry. <i>Clinical Research in Cardiology</i> , 2018, 107, 653-657.	1.5	30
47	Early diagnosis of acute myocardial infarction using high-sensitivity troponin I. <i>PLoS ONE</i> , 2017, 12, e0174288.	1.1	29
48	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. <i>Circulation</i> , 2022, 145, 1254-1284.	1.6	29
49	Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock. <i>Journal of Clinical Medicine</i> , 2020, 9, 931.	1.0	28
50	Effects of COVID-19 on in-hospital cardiac arrest: incidence, causes, and outcome – a retrospective cohort study. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2021, 29, 30.	1.1	28
51	cAMP Imaging at Ryanodine Receptors Reveals β_2 -Adrenoceptor Driven Arrhythmias. <i>Circulation Research</i> , 2021, 129, 81-94.	2.0	28
52	Challenging the 99th percentile: A lower troponin cutoff leads to low mortality of chest pain patients. <i>International Journal of Cardiology</i> , 2017, 232, 289-293.	0.8	27
53	Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 1031-1036.	0.6	27
54	Risk prediction of in-hospital mortality in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: The ECMO-ACCEPTS score. <i>Journal of Critical Care</i> , 2020, 56, 100-105.	1.0	27

#	ARTICLE	IF	CITATIONS
55	New perspective on the tissue kallikrein-kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration. <i>International Immunopharmacology</i> , 2008, 8, 148-154.	1.7	26
56	Risk Factors of Coronary Artery Disease in Secondary Prevention-Results from the AtheroGene Study. <i>PLoS ONE</i> , 2015, 10, e0131434.	1.1	26
57	High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 401-411.	1.9	26
58	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. <i>Heart</i> , 2021, 107, 229-236.	1.2	26
59	Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause- The Cardiogenic Shock Score. <i>European Journal of Heart Failure</i> , 2022, 24, 657-667.	2.9	26
60	Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8727-E8736.	3.3	25
61	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021, 23, 1942-1951.	2.9	25
62	High-sensitivity cardiac troponin I after coronary artery bypass grafting for post-operative decision-making. <i>European Heart Journal</i> , 2022, 43, 2388-2403.	1.0	23
63	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. <i>Biological Chemistry</i> , 2008, 389, 713-718.	1.2	22
64	Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts. <i>Biomolecules</i> , 2019, 9, 38.	1.8	20
65	Renin inhibitors, clinical experience. <i>Journal of Molecular Medicine</i> , 2008, 86, 691-695.	1.7	19
66	Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-17.	0.9	19
67	Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. <i>Current Opinion in Critical Care</i> , 2019, 25, 391-396.	1.6	19
68	Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 283, 35-40.	0.8	19
69	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	0.7	18
70	Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes. <i>Diabetes Care</i> , 2020, 43, 460-467.	4.3	18
71	Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , 2021, 8, e001499.	0.9	18
72	Relative Telomere Length and Cardiovascular Risk Factors. <i>Biomolecules</i> , 2019, 9, 192.	1.8	17

#	ARTICLE	IF	CITATIONS
73	Sex differences in patients with cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 1775-1783.	1.4	17
74	Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: results from the AtheroGene study. <i>Biomarkers</i> , 2017, 22, 210-218.	0.9	16
75	Epidemiology of intensive care unit cardiac arrest: Characteristics, comorbidities, and post-cardiac arrest organ failure – A prospective observational study. <i>Resuscitation</i> , 2020, 156, 92-98.	1.3	16
76	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock. <i>Journal of the American Heart Association</i> , 2022, 11, e024932.	1.6	15
77	Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2022, 16, 799-811.	1.3	15
78	SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. <i>Clinical Research in Cardiology</i> , 2016, 105, 901-911.	1.5	13
79	Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. <i>Journal of Critical Care</i> , 2020, 57, 253-258.	1.0	13
80	Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017, 40, 1197-1204.	0.7	12
81	Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction. <i>Biomolecules</i> , 2019, 9, 469.	1.8	12
82	Single-dose of adreuzumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 247-254.	5.2	12
83	Activity of superoxide dismutase copper/zinc type and prognosis in a cohort of patients with coronary artery disease. <i>Biomarkers in Medicine</i> , 2015, 9, 597-604.	0.6	11
84	TAVR for low-flow, low-gradient aortic stenosis: Prognostic impact of aortic valve calcification. <i>American Heart Journal</i> , 2020, 225, 138-148.	1.2	11
85	Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BASILICA experience. <i>Clinical Research in Cardiology</i> , 2021, 110, 1900-1911.	1.5	11
86	The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease. <i>Biomarkers in Medicine</i> , 2015, 9, 731-741.	0.6	10
87	Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. <i>Clinical Research in Cardiology</i> , 2019, 108, 1386-1393.	1.5	10
88	Response by Schrage and Westermann to Letters Regarding Article, “Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study.” <i>Circulation</i> , 2021, 143, e1024.	1.6	10
89	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	0.8	9
90	Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction. <i>Biomolecules</i> , 2019, 9, 108.	1.8	8

#	ARTICLE	IF	CITATIONS
91	Distinct Hemodynamic Changes After Interventional Mitral Valve Edge-to-Edge Repair in Different Phenotypes of Heart Failure: An Integrated Hemodynamic Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	7
92	The association of anaemia and high-sensitivity cardiac troponin and its effect on diagnosing myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, , .	0.4	7
93	Association of high-sensitivity troponin T and I with the severity of stable coronary artery disease in patients with chronic kidney disease. <i>Atherosclerosis</i> , 2020, 313, 81-87.	0.4	6
94	Diagnosing myocardial infarction: a highly sensitive issue. <i>Lancet, The</i> , 2018, 392, 893-894.	6.3	5
95	Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. <i>Biomarkers in Medicine</i> , 2020, 14, 775-784.	0.6	5
96	Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. <i>Open Heart</i> , 2021, 8, e001726.	0.9	5
97	Extracorporeal membrane oxygenation. <i>Deutsches A&#x0308;rztblatt International</i> , 2022, , .	0.6	5
98	Mitral stenosis and atrial fibrillation. <i>Heart</i> , 2020, 106, 713-713.	1.2	4
99	Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI. <i>Open Heart</i> , 2022, 9, e001912.	0.9	4
100	Intracranial haemorrhage in adult patients on venoarterial extracorporeal membrane oxygenation. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 303-311.	0.4	4
101	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	0.7	3
102	Establishing a robotic-assisted PCI program: experiences at a large tertiary referral center. <i>Heart and Vessels</i> , 2022, 37, 1669-1678.	0.5	3
103	Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1470-1477.	0.8	2
104	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 364-365.	1.9	2
105	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <i>Journal of Cardiology</i> , 2021, , .	0.8	2
106	More evidence for high-sensitivity troponin assays. <i>Heart</i> , 2018, 105, heartjnl-2018-314280.	1.2	1
107	Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19 – A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2195.	1.0	1
108	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. <i>Critical Care</i> , 2021, 25, 325.	2.5	1

#	ARTICLE	IF	CITATIONS
109	Radiation exposure during the implantation of bioabsorbable vascular scaffolds versus drug-eluting stents in non-complex coronary lesions: a matched-cohort study. <i>Minerva Cardiology and Angiology</i> , 2016, 65, 1-7.	0.4	1
110	De-escalation of support with venoarterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 622-623.	2.9	0
111	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2941.	1.2	0
112	Detailed interpretation of ECMO-ACCEPTS score. <i>Journal of Critical Care</i> , 2020, 60, 327.	1.0	0
113	The matricellular proteins thrombospondin-2, osteonectin and osteoglycin modulate cardiac inflammation, injury and function during viral myocarditis.. <i>FASEB Journal</i> , 2012, 26, 1060.6.	0.2	0
114	Osteoglycin (OGN) modulates inflammation during viral myocarditis via an interaction with Toll Like Receptor 4.. <i>FASEB Journal</i> , 2013, 27, 829.1.	0.2	0
115	Extracorporeal Membrane Oxygenation Evolution: LV Unloading Strategies. <i>JTCVS Open</i> , 2021, , .	0.2	0